Multiple primary melanomas in a CDKN2A mutation carrier exposed to ionizing radiation by Eliason, M. J. et al.
OBSERVATION
Multiple Primary Melanomas in a CDKN2A Mutation
Carrier Exposed to Ionizing Radiation
Mark J. Eliason, MD; Chris B. Hansen, MD; Marybeth Hart, MS; Patricia Porter-Gill, BS; Wei Chen, BM, MD;
Richard A. Sturm, PhD; Glen Bowen, MD; Scott R. Florell, MD; Ronald M. Harris, MD, MBA;
Lisa A. Cannon-Albright, PhD; Leonard Swinyer, MD; Sancy A. Leachman, MD, PhD
Background: Recent research has shown a possible
causal relationship between ionizing radiation expo-
sure and melanoma. Individuals with mutations in
CDKN2A (cyclin-dependent kinase inhibitor 2A), the ma-
jor melanoma predisposition gene, have an increased sus-
ceptibility to melanoma-promoting exposures, such as
UV light. We describe a patient from a familial mela-
noma pedigree with 7 primary melanomas on the right
side of her body, the first occurring 5 years after expo-
sure to atmospheric nuclear bomb testing in the 1950s.
Observations: Physical examination revealed photo-
type I skin, red hair, and 26 nevi (14 on the right and 12
on the left side of her body). One nevus was larger than
5 mm, and 2 were clinically atypical. Sequence analysis
demonstrated a known deleterious mutation inCDKN2A
(G−34T) and homozygosity for a red hair color variant
in MC1R (melanocortin 1 receptor) (R151C). Fluores-
cence in situ hybridization analysis of blood, fibro-
blasts, and melanocytes from both upper extremities ruled
out mosaicism.
Conclusions: Individuals such as this patient, who has
CDKN2A andMC1Rmutations, are likely to be more sus-
ceptible to environmental insults. A careful review of en-
vironmental exposures in these vulnerable cases may re-
veal cancer-promoting agents, such as ionizing radiation,
that go unnoticed in less susceptible populations.
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R ISK FACTORS FOR MELA-noma include environmen-tal insults (eg, blisteringsunburns) and genetic fac-tors underlying hair and eye
color, skin type, many or atypical moles,
and family history. Being a member of a
melanoma-prone family is the most sig-
nificant risk factor, increasing one’s like-
lihood of developing a melanoma to 35 to
70 times that of the general population.1
The gene for cyclin-dependent kinase in-
hibitor 2A (CDKN2A or p16) is the major
melanoma predisposition gene identified
at present. p16 is a key regulator of G1/S
cell cycle entry by controlling phosphory-
lation of retinoblastoma via inhibition of
cyclin-dependent kinases 4 and 6 (CDK4
and CDK6).2 Variants in the gene for the
melanocortin 1 receptor (MC1R) alter the
production of pigment, shifting the equi-
librium from eumelanin to pheomelanin.
MC1R is a low-penetrance melanoma sus-
ceptibility gene; heterozygotes for the
R151C allele have a 2-fold increased risk,
and homozygotes such as the patient de-
scribed herein carry an approximate 4-fold
risk to develop melanoma compared with
the general population.3 Carriage ofMC1R
variants by those with the CDKN2A mu-
tation confers an additional risk for mela-
noma development.4-7
The relationship between environmen-
tal and genetic factors is illustrated by
international investigations of CDKN2A
mutation carriers. The GenoMel, an in-
ternational Melanoma Genetics Consor-
tium (http://www.genomel.org/), re-
ported that the lifetime prevalence of
melanoma among individuals with
CDKN2Amutations varied considerably by
geographic locale.8 The lifetime inci-
dence of melanoma was 58% in Europe,
76% in the United States, and 91% in Aus-
tralia among CDKN2A carriers of similar
ethnic backgrounds. Bishop et al8 sug-
gested that this difference was best ex-
plained by the difference in UV exposure
and UV sensitivity among the different
populations. The CDKN2A mutation car-
rier population clearly represents the group
most likely to develop melanoma, and
through careful history and observation,
researchers may be able to deduce other
melanoma-promoting events that may not
be obvious in the general population.
Ionizing radiation is a known muta-
gen and carcinogen. Long- and short-
term exposures have been associated with
leukemia and thyroid, breast, and lung
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cancers.9,10 Studies that tracked the rates of cancer in the
atomic bomb survivors of Nagasaki and Hiroshima re-
ported an increased rate of basal cell and squamous cell
carcinomas, but not melanoma, among this exposed Japa-
nese population. In 2005, Fink and Bates11 published a
meta-analysis of melanoma in 7 cohorts of individuals
with short- or long-term exposure to ionizing radiation.
Most of these groups included large white populations,
the race most susceptible to melanoma development, and
not represented by the work on Nagasaki and Hiro-
shima survivors. The authors reported a statistically sig-
nificantly increased relative risk of melanoma in 5 of their
7 cohorts, including a cohort of 3702 subjects involved
in the 1957 above-ground nuclear testing.11
A large, retrospective analysis of individuals treated
with ionizing radiation for hereditary retinoblastoma dem-
onstrated a significantly elevated rate of melanomas in
the treatment field.12 This would suggest that in geneti-
cally predisposed individuals, exposure to ionizing ra-
diation can promote melanoma through the retinoblas-
toma pathway. The CDKN2A protein product, p16,
regulates cell growth through the retinoblastoma path-
way,13 but the effects of ionizing radiation on CDKN2A
mutation carriers have yet to be studied. In a 2005 study
of multiple primary melanomas (MPM) andCDKN2Amu-
tations, Puig et al14 noted that one of their patients with
MPM had a CDKN2A mutation and a history of long-
term exposure to ionizing radiation. We herein describe
a CDKN2A mutation carrier with 7 primary melanomas
on the same side of her body and a unique history of ex-
posure to ionizing radiation.
OBSERVATIONS
The patient is a white woman who underwent investi-
gation for a history of MPM. Medical records and blood
and tissue samples were collected for investigation.
Her medical history was remarkable for the develop-
ment of a melanoma on her right ear at 28 years of age,
treated by excision and a radical neck lymph node dissec-
tion (Figure 1). She subsequently developed 6 addi-
tional primary melanomas. Of the 7 total melanomas, 6 were
found on the right side of her body and 1 was in the mid-
line (Figure 2). A squamous cell carcinoma of her right
upper lip was diagnosed in 1997. Other pertinent medical
history includes a 46-year history of smoking, coronary ar-
tery disease with placement of 3 coronary artery stents, and
polycythemia vera diagnosed at 63 years of age.
Her environmental exposure history was significant
for 1 blistering sunburn before 20 years of age, with mini-
mal sunbathing and no subsequent sunburns. She also
reports 1 episode of intense exposure to ionizing radia-
tion at 27 years of age that occurred in October 1958 in
southern Utah and Nevada. The patient and her hus-
band left the car in which they were traveling to observe
an atmospheric nuclear detonation from an undeter-
mined distance for 20 to 30 minutes. After leaving the
blast site, the patient sat in the passenger side of the car,
the side oriented toward the test site, riding with her arm
outside the car. They noted a fine, sticky dust on the top
of the car when they arrived home, consistent with nuclear
fallout. The patient denies the development of nausea or
other acute symptoms the day of the exposure.
Her family history includes a cousin with melanoma and
melanoma in the children of another cousin. Multiple other
cancer types were also described in her extended family.
PHYSICAL EXAMINATION
Pertinent findings included phototype I skin, green eyes,
red hair, and mild freckling. On the right side of her body,
the patient had 14 moles, 1 of which was atypical. No
nevi were larger than 5 mm. She also had 12 well-healed
biopsy and treatment scars. On the left side of her body,
the patient had 12 moles, 1 larger than 5 mm and 1 with
atypical features, and 5 well-healed biopsy scars.
LABORATORY TESTS
Results of routine laboratory tests, including complete
blood cell count, liver function tests, and a lipid panel,
were unremarkable other than an elevated hematocrit con-
sistent with polycythemia vera. Sequencing of the
CKDN2A gene and promoter region revealed a G−34T
5 UTR mutation known to be deleterious.15 No addi-
tional mutations were found within the coding region.
The alternate reading frame gene was also sequenced and
had no mutations. Sequencing ofMC1Rdemonstrated that
the patient was homozygous for the R151C mutation.
Chromosomal studies were performed on melanocytes,
peripheral blood, and fibroblasts. Tissue specimens were
collected from both sides of the body. Metaphase cells
analyzed from cultures of all these tissues revealed a nor-
Figure 1. Right side of the patient’s face at the time she underwent evaluation in
our clinic. The right external ear had been removed approximately 40 years
previously owing to melanoma and it healed well. The patient’s phototype I skin,
red hair, and external auditory canal are apparent.
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mal female karyotype. Fluorescence in situ hybridiza-
tion of all specimen types was performed, and no chro-
mosomal abnormalities were found. Direct sequencing
of MC1R was performed as previously described.4,16,17
COMMENT
This is a unique case report of ionizing radiation expo-
sure in an individual with a deleterious CDKN2A muta-
tion and MPM. The patient had 7 primary melanomas dur-
ing a course of about 30 years, starting late in her third
decade of life. Her laboratory studies are significant for a
deleteriousCDKN2Amutation, homozygosity for anMC1R
red hair color variant, and fluorescence in situ hybridiza-
tion results that were negative for chromosomal aber-
rancy on either side of her body. Her physical examina-
tion revealed skin phototype I, red hair, numerous biopsy
and excisional scars, and a random distribution of 26 nevi,
2 of which had atypical features. Most of her melanomas
occurred in traditionally sun-protected areas. Her family
history is consistent with hereditary melanoma.1
Many groups have investigated the correlation be-
tween MPM andCDKN2Amutations (Table).14,18-24 Col-
lectively, these groups have described 467 individuals with
MPM, 70 of them (15.0%) withCDKN2Amutations. Not
all groups specified the number of primary melanomas
for each individual. Of the studies that did specify the
number of primary melanomas,14,18,19,23,24 5 of 311 cases
(1.6%) had at least 7 primary melanomas. Even among
individuals with CDKN2A mutations, it is rare to have 7
primary melanomas. Puig et al14 reported that among their
104 patients with MPM, only 3 had a second primary
melanoma appear in proximity (defined as on the same
extremity as the first melanoma).14 Our patient was ini-
tially seen with a grouping of 4 independent melanomas
on the right side, 1 on the inner left thigh, and 3 mela-
nomas close to one another on the right ear, right shoul-
der, and upper back area (Figure 2).
Her exposure history is significant for 1 blistering sun-
burn and her report of observing an above-ground nuclear
test while traveling in Utah and Nevada. The time of the
exposure she describes is chronologically consistent with
Operation Hardtack II (September 12 to October 30,
1958), during which atmospheric nuclear testing took
place in southern Nevada.25,26
Previous studies have linked exposure to ionizing ra-
diation and nonmelanoma skin carcinomas, including leu-
kemia and thyroid, breast, and lung cancers.9,27,28 There
are also several brief reports that have described an ex-
cess rate of polycythemia rubra vera in subjects exposed
to the fallout of nuclear tests.29,30 Ionizing radiation has
not been historically considered a promoting agent for
melanoma, because many of the original studies that re-
viewed the cancer in atomic blast survivors in Japan did
not identify melanoma as an outcome of interest.
A B
Right
Right
Right
Left
Not applicable
Right
Right
Ear
Leg
Thigh
Inner thigh
Middle upper back
Popliteal fossa
Upper lateral arm
MM
MM
SSM in situ
SSM in situ
SSM
SSM
MM in situ
Laterality Location Diagnosis
Figure 2. The location of the melanoma sites in the patient. A, Locations are approximated by the dots. The red dot indicates a melanoma that occurred on the
anterior surface of the participant. B, Location and diagnosis of melanoma. MM indicates melanoma; SSM, superficial spreading melanoma.
Table. Overview of Studies Published on CDKN2A Testing
in Patients With MPMs
Source
Total
MPM
Cases, No.
Characteristics of MPM Cases
(Cases With CDKN2A
Mutations, No.)
Puig et al,14 2004 104 1 Case, 7 PM (1); 2 cases, 6 PM (1);
1 case, 5 PM (1); 5 cases, 4 PM
(2); all other cases, 3 PM (12)
Blackwood et al,18
2002
96 1 Case, 9 PM (0); 1 case, 7 PM (1);
2 cases, 6 PM (1); 2 cases, 5 PM
(0); 4 cases, 4 PM (1); all other
cases, 3 PM (6)
Hashemi et al,19
2000
80 1 Case, 6 PM (0); 2 cases, 5 PM (0);
4 cases, 4 PM (2); all other cases,
3 PM (7)
Monzon et al,20
1998
33 3 Cases, 3 PM (1); all other cases,
3 PM (4)
Auroy et al,21
2001
100 4 Cases, 5 PM (3); 2 cases, 4 PM
(0); all other cases, 3 PM (6)
Mantelli et al,22
2002
23 3 Cases, 3 PM (3); all other cases,
2 PM (8)
Mackie et al,23
1998
17 1 Case, 8 PM (1); No. of PM in other
cases not stated (1)
Eliason et al,24
2006
14 1 Case, 7 PM (1); all other cases,
3 PM (7)
Total 467 70 Cases, MPM (70)
Abbreviations: MPM, multiple primary melanomas; PM, primary
melanomas.
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The studies reviewed by Fink and Bates11 collectively
totaled hundreds of thousands of individuals who were pre-
dominantly white, the population most susceptible to mela-
noma. In addition to the rates of melanoma, the authors
reported which of these studies demonstrated an excess rate
of leukemia as a means to distinguish which cohorts re-
ceived a significant radiation exposure. Five of the 7 co-
horts had elevated rates of leukemia and melanoma. The
remaining 2 cohorts did not have excess melanoma or ex-
cess leukemia, suggesting that both did not receive suffi-
cient irradiation to induce any malignancy. They con-
clude that melanoma has not always been considered a
significant end point in epidemiological studies on ioniz-
ing radiation, which may have hampered identifying a po-
tentially causal relationship between ionizing radiation and
melanoma. They also recommend that future epidemio-
logical studies of ionizing radiation consider inclusion of
melanoma as an outcome of interest.11
It is not clearly understood why some patients with
CDKN2Amutations never develop melanoma, whereas oth-
ers with the same mutation and even in the same family
seem exquisitely prone to the development of numerous
primary lesions. We suggest that in our patient, the MPM
may have been a result of the superimposition of environ-
mental exposures (ionizing radiation) on her highly vul-
nerable genetic predisposition. The careful examination
of phenotypic and environmental risk factors in the very
vulnerable subpopulation of CDKN2A mutation carriers
may be a strategy to identify and clinically verify risk fac-
tors less obvious in the general population.
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